Tirzepatide is a medication that improves insulin sensitivity, which can be evaluated indirectly through fasting biomarkers such as glucose and insulin and the homeostasis model assessment of insulin resistance (HOMA2-IR). This evidence concerns the gene INS and Insulin resistance.